Treatment
Ambrisentan clinical trials
We’re tracking 4 recruiting studies that include Ambrisentan, each written for real people, not researchers, below.
Recruiting studies
- NCT07013149Recruiting
Switching PAH medicines: does it change your risk?
This study looks at how changing from one PAH medicine (ambrisentan) to another (bosentan) affects your disease risk over time. It compares people who made the switch to those who stayed on ambrisentan.
São Paulo, São PauloAges 18 years+ - NCT06968962Recruiting
Starting PAH treatment: one drug first or two drugs together?
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
Hangzhou, ZhejiangAges 18–80 - NCT07030894RecruitingPhase 4
Study of Nefecon and Ambrisentan for IgA Nephropathy
This trial tests two medications, Nefecon and Ambrisentan, to see if they can help people with IgA nephropathy, a kidney disease. It may be an option if you have been diagnosed with IgA nephropathy in the last 4 years and have protein in your urine.
Changchun, JilinAges 18–70 - NCT07245680RecruitingPhase 3
Testing two pills vs one for pulmonary hypertension with heart or metabolism issues
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Le Kremlin-BicêtreAges 18 years+
What Ambrisentan is being studied for
Conditions with recruiting Ambrisentan studies.
Common questions
- Are there clinical trials studying Ambrisentan?
- Yes. Clin2 currently lists 4 recruiting studies that include Ambrisentan, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ambrisentan trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ambrisentan an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ambrisentan or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.